secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001517022-25-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q2 2025 net income $0.2M vs loss; Vafseo rev $13.3M, DaVita pilot in 100+ clinics
--------------------------------------------------------------------------------

- Net income $0.2M (vs net loss of $8.6M in Q2 2024); total revenue $62.5M, up 43%.
- Vafseo net product revenue $13.3M; prescription demand grew ~55% QoQ; >725 prescribers.
- DaVita begins operational pilot in August at 100+ clinics; DCI/IRC protocols by Sept.
- Auryxia net revenue $47.2M, up from $41.2M; no ANDA approved despite LOE in March.
- Cash $137.3M; company believes financed to profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/0001517022-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/akba-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer